DIPEPTIDYL PEPTIDASE-4 INHIBITOR HAS BENEFICIAL EFFECTS ON POST-MYOCARDIAL INFARCTION HEART IN DIABETIC MICE

被引：0
|
作者：
Kubota, Akihiko [1 ]
Hasegawa, Hiroshi [1 ]
Kameda, Yoshihito [1 ]
Yuka, Kobara [1 ]
Tadokoro, Hiroyuki [1 ]
Kobayashi, Yoshio [1 ]
Komuro, Issei [1 ]
Takano, Hiroyuki [1 ]
机构：
[1] Chiba Univ, Grad Sch Med, Dept Cardiovasc Med, Chiba, Japan
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2013年 / 61卷 / 10期
关键词：
D O I：
10.1016/S0735-1097(13)60596-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E596 / E596
页数：1
相关论文
共 50 条
  • [31] Biological function of dipeptidyl peptidase-4 on type 2 diabetes patients and diabetic mice
    Qiao, Jing
    Li, Lei
    Ma, Yanchun
    Shi, Ruhui
    Teng, Mei
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2019, 67 (03) : 89 - 92
  • [32] Cardioprotective Effects of Dipeptidyl Peptidase-4 Inhibition on Pressure Overload-induced Heart Failure in Mice
    Hasegawa, Hiroshi
    Kobara, Yuka
    Kameda, Yoshihito
    Kubota, Akihiko
    Tadokoro, Hiroyuki
    Kobayashi, Yoshio
    Komuro, Issei
    Takano, Hiroyuki
    CIRCULATION, 2012, 126 (21)
  • [33] Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Suppressed Abdominal Aortic Aneurysm Formation in Mice
    Takahara, Yusuke
    Tokunou, Tomotake
    Ichiki, Toshihiro
    Sunagawa, Kenji
    DIABETES, 2015, 64 : A113 - A113
  • [34] Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor
    Takahara, Yusuke
    Tokunou, Tomotake
    Ichiki, Toshihiro
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (08) : 698 - 708
  • [35] The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin has the Capacity to Repair β-Cell Dysfunction and Insulin Resistance
    Horie, A.
    Tokuyama, Y.
    Ishizuka, T.
    Suzuki, Y.
    Marumo, K.
    Oshikiri, K.
    Ide, K.
    Sunaga, M.
    Kanatsuka, A.
    HORMONE AND METABOLIC RESEARCH, 2014, 46 (11) : 814 - 818
  • [36] A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
    Satoh-Asahara, Noriko
    Sasaki, Yousuke
    Wada, Hiromichi
    Tochiya, Mayu
    Iguchi, Azusa
    Nakagawachi, Reiko
    Odori, Shinji
    Kono, Shigeo
    Hasegawa, Koji
    Shimatsu, Akira
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (03): : 347 - 351
  • [37] The dipeptidyl peptidase-4 inhibitor linagliptin exerts neurotrophic effects in the olfactory cortex of type 2 diabetic rats
    Lietzau, G.
    Ostenson, C. -G.
    Nystrom, T.
    Klein, T.
    Darsalia, V.
    Patrone, C.
    DIABETOLOGIA, 2016, 59 : S282 - S282
  • [38] MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice
    Bhattacharjee, Alpana
    Allister, Emma M.
    Wheeler, Michael B.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2012, 90 (05) : 663 - 668
  • [39] The suppressive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to the action of incretin in both non-diabetic and diabetic mice
    Terasaki, M.
    Nagashima, M.
    Nohtomi, K.
    Kohashi, K.
    Tomoyasu, M.
    Shinmura, K.
    Nogi, Y.
    Sato, K.
    Itoh, F.
    Watanabe, T.
    Hirano, T.
    DIABETOLOGIA, 2013, 56 : S69 - S70
  • [40] Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
    Dicembrini, Ilaria
    Mannucci, Edoardo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 184 : 543 - 544
12345